Search
All Clinical Trials
A listing of 23137 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
2041 - 2052 of 23137
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Study of Endocrine-Related Conditions and Physiology
Recruiting
Background:
Endocrine disorders involve changes to glands that produce hormones. Hormones are released by these glands into the blood so they can direct the function of other tissues in the body. Researchers want to study people who may have endocrine disorders. They want to learn more about the conditions that affect endocrine glands.
Objective:
To study adults with a variety of endocrine disorders for research and physician education.
Eligibility:
Adults ages 18 and older who have an endo... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
04/18/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Endocrine Disease
Implementation Supports to Reduce Burnout in Therapists Delivering Child Trauma EBPs
Recruiting
The majority of children exposed to early adversity and trauma do not have access to sustainably delivered evidence-based mental health programs (EBPs), despite the growing prevalence of large-scale multiple-EBP implementation efforts aimed at increasing access to these services. The objective of this proposal is to develop and test a package of implementation strategies designed to promote the sustained delivery of child trauma EBPs by reducing provider turnover through targeting the associated... Read More
Gender:
ALL
Ages:
Between 3 years and 99 years
Trial Updated:
04/18/2025
Locations: San Diego State University, San Diego, California
Conditions: Mental Health Issue
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
Recruiting
This phase 1 pilot study examines the feasibility and safety of mosunetuzumab after autologous stem cell transplant for patients with aggressive B cell lymphomas. Mosunetuzumab is an antibody that has been engineered to attach to two target cells in the immune system: T cells that normally perform tasks like killing virus-infected cells, and cancerous B cells. Mosunetuzumab has been designed to direct these T cells to kill the cancerous B cells instead.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: B Cell Lymphoma, Aggressive Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma, Follicular Lymphoma Grade 3
Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED
Recruiting
The primary objective of the study is to investigate the safety and efficacy of KPI-012 compared to vehicle in participants who have a documented clinical diagnosis of PCED.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Principal Investigator, Dothan, Alabama +46 locations
Conditions: Persistent Corneal Epithelial Defect
Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction
Recruiting
This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-861 administered once daily for 12 weeks in subjects with heart failure with reduced ejection fraction (HFrEF) who are on a stable, guideline-directed medical therapy for heart failure.
Gender:
ALL
Ages:
Between 30 years and 85 years
Trial Updated:
04/18/2025
Locations: Nature Coast Clinical Research, Crystal River, Florida +52 locations
Conditions: Chronic Heart Failure
Study to Assess the Efficacy and Safety of Iovera®° System in Subjects With Upper Extremity Spasticity
Recruiting
This multicenter, randomized, double-blind, sham-controlled study is designed to evaluate the efficacy and safety of the iovera° system in subjects with upper extremity spasticity. A total of approximately 132 subjects will be enrolled; 88 subjects will receive treatment with the iovera° system and 44 subjects will receive sham treatment (sham iovera° system treatment).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Source Healthcare - Santa Monica, Santa Monica, California +16 locations
Conditions: Spasticity, Cerebral or Spinal Condition
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
Recruiting
The objective of this study is to assess the potential for tezepelumab-treated patients (subcutaneous administration) to reduce maintenance therapy without loss of asthma control in adolescent and adults with severe asthma..
Study details include:
1. The study duration will be up to 72 weeks.
2. The treatment duration will be up to 68 weeks.
3. The visit frequency will be once every 4 weeks (Q4W).
Gender:
ALL
Ages:
Between 12 years and 80 years
Trial Updated:
04/18/2025
Locations: Research Site, Palmdale, California +83 locations
Conditions: Severe Asthma
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Recruiting
The main goal of this trial is to study the frequency and severity of cytokine release syndrome (CRS) in participants with diffuse large B-cell lymphoma (DLBCL) who are using a combination of glofitamab + gemcitabine + oxaliplatin (Glofit-GemOx) followed by glofitamab-only treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Alaska Oncology & Hematology, LLC, Anchorage, Alaska +9 locations
Conditions: Diffuse Large B-Cell Lymphoma
National Eye Institute Biorepository for Retinal Diseases
Recruiting
Background:
- To understand diseases of the retina and the eye, information is needed about people with and without such diseases. Researchers want to study these people and follow them over time. They also want to study body tissues and blood to understand the nature of eye disease. Studying genes, cells, and tissues may help them understand why some people get eye problems and others do not, or why some people respond to treatment while others do not. Researchers want to collect physical samp... Read More
Gender:
ALL
Ages:
Between 2 years and 120 years
Trial Updated:
04/18/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Age-Related Macular Degeneration, Diabetic Retinopathy, Von Hippel-Lindau Syndrome, Retinal Disease, Retinal Vein Occlusion
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Recruiting
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +61 locations
Conditions: Glioblastoma
Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma
Recruiting
This study investigates the extent to which lifestyle factors including mental health, social support, diet, and exercise are associated with quality of life and melanoma patient outcomes. Knowledge gained from this study may be used to guide the design of prospective clinical trials of lifestyle interventions to improve the outcomes of melanoma patients and assist doctors in counseling their patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Cutaneous Melanoma
Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis
Recruiting
Background:
Diffuse midline gliomas are the most aggressive brain tumors of childhood and young adults. Most people with these tumors survive less than 2 years. Researchers want to see if an anticancer drug (abemaciclib) can help.
Objective:
To see if researchers can measure how much abemaciclib is in a person's brain tumor and brain fluid after they take the drug for a few days.
Eligibility:
People aged 18 to 39 with recurrent high-grade glioma or diffuse midline glioma.
Design:
Particip... Read More
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
04/18/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Glioma
2041 - 2052 of 23137